Arnicare Bruise Tablet
Product Images NDC 0220-9083

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Arnicare Bruise (NDC 0220-9083). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Boiron, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Arnicare Bruise Tablets Etu.1gyc 11.2021)

Drug Facts panel for Arnicare Bruise tablets containing Arnica Montana 9 HPUS 2.5 mg. The panel details active ingredient, purpose, uses for bruising symptoms, warnings, directions for different age groups, inactive ingredients, and contact information for Boiron. It includes Boiron's commitment to product quality and indicates the product is made in France.*

FDA Label Image

Arnicare Bruise Tablets Foil Alu.1gyd

Text panel from Arnicare Bruise 9C tablets by Boiron providing dosing instructions for bruise relief. It directs adults and children 6 years and older to dissolve tablets in the mouth with specific timing, with separate instructions for children aged 2 to 5 years involving dissolving tablets in water, and advises consultation for children under 2 years.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.